Co-founder and CEO of Advanced Biological Laboratories SA, Chalom Sayada previously served as CEO of Sequoia Pharmaceuticals Inc (2004), President and CEO of ActivBiotics Inc. (2000-2003), Vice President at Visible Genetics (1998-2000), President and CEO of ACT Gene SA (1996-1998) which was acquired by Visible Genetics Inc (NASDAQ) in 1998, and Product and Scientific Manager for Roche Diagnostics (1993-1996). Chalom has extensive experience gained from his positions in early and clinical development at pharmaceutical and diagnostics companies in the United States and Europe. He has helped raise more than $50 million in venture capital financing, completed international in- and out-licensing agreements and has a broad experience in infectious diseases, oncology and human genetic diseases.
Founder and CEO of a new Biotech venture, MindSet Rx, Bernard Malfroy-Camine was previously CEO of Eukarion, a company he had founded in 1991, which was acquired by Proteome Systems in 2005. Following the acquisition Bernard held the position of Executive VP Therapeutics at Proteome Systems. Formerly he was Director of Development at Alkermes and a scientist at Genentech. He is also a co-founder of Palumed, a French biotechnology company, and serves as member of its Board of Directors, and Deputy Director for Alliances. In 2002 he was awarded the Chevalier de L’Ordre National du Mérite for his contributions to biotechnology in France and in the USA and appointed as a Foreign Trade Advisor to the French government.
Bernard graduated from Ecole Polytechnique, Paris, in 1976, and earned a Ph.D. in Neurobiology from University Paris VI in 1982. He started his scientific career as a researcher at CNRS, France, and has more than 80 scientific publications and over a dozen patents.
Following the merger between SG Asset Management and CA Asset Management in 2010 to form Amundi, Jean-Yves has left this Group and organize the transfer of the management of the FCPR Biotechnology Fund, which he managed since 2001, to a new management Company, Vesale Partners. Vesale Partners, which has received AMF agreement under number GP-12000021, has been founded by Jean-Yves and Vesalius Biocapital in 2011.
Jean-Yves Nothias joined SGAM in 2000 and lead the Biotechnology Team as Managing Director at SG Asset Management Alternative Investments (SGAM AI) from 2000 to 2011 He built a team of professionals that manage a global portfolio of 34 biotechnology companies.
Previously, he was a biotechnology analyst for Hambrecht & Quist, Paris, and then for Oddo & Cie. Jean-Yves is on the supervisory board of two US biotech companies: GenomeQuest and Scynexis and in addition to Genomic Vision two other French biotech companies: Ingen, and Biosystems International.
Previously Jean-Yves worked as a scientist at several research institutions in France and the United States and from 1993 until 1995 was a post-doctoral fellow at the Roche Institute of Molecular Biology in Nutley, N.J., USA.
Jean-Yves holds a doctorate in Molecular Biology from the Université Paris VI and a master’s degree in management from Université Paris Sorbonne.
Currently a Partner at Vesalius Biocapital, Stéphane Verdood has 25 years’ experience as a Business Consultant in the healthcare, pharmaceutical and biotechnology industries. He co-founded Value for Growth in 2001 as a venture coach for mainly young biotechnology companies and has assisted more than 10 start-up companies in fundraising. Stéphane worked for more than 15 years at Arthur Andersen as a business consultant to the pharmaceutical industry. He successfully merged and reorganized hospitals in Europe and re-structured European pharmaceutical companies in the areas of R&D, distribution and sales. In 1995 he founded Andersen Business Consulting in Belgium.
Stéphane holds a M.Sc. in commercial engineering as well as a MBA from the University of Leuven.